GSK suffers another R&D setback, axing ulcerative colitis drug trialGlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in Share XGSK suffers another R&D setback, axing ulcerative colitis drug trialhttps://pharmaphorum.com/news/gsk-suffers-another-rd-setback-axing-ulcerative-colitis-drug-trial/
